Healthcare Dec 31, 2021 02:00 PM (GMT+8) · EqualOcean
On December 31, Junshi biological revealed that, The Ministry of health of Uzbekistan has approved the emergency use authorization (EUA) of oral nucleoside anti COVID-19 drug VV116 for the treatment of new crown patients. VV116 was jointly developed by the Shanghai Institute of Materia Medica, China Academy of Sciences, Wuhan Institute of Chinese Academy of Sciences, Xinjiang Institute of physical and chemical technology, China Academy of Sciences, Wang Shan Wang, and China Pharmaceutical Research and development center of China Academy of Sciences.